Cancer Cooperative Group Leaders Propose A Re-Engineering of the Nation's Correlative Science Program for Cancer

September 19, 2024

The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks

__________________________

With publicly funded correlative science in the na

• Read more

New Trial Alert: Alliance A062101 Relapsed or Refractory Multiple Myeloma

September 17, 2024

Alliance A062101: A phase I/II study of the safety, tolerability and efficacy of belantamab mafodotin (GSK2857916) in combination with iberdomide (CC-220)/dexamethasone versus belantamab mafodotin (GSK2857916)/dexamethasone in relapsed refractory multiple myeloma

Monique A. Hartley-Brown, MD, MMSc, of Dana-Farber Cancer Institute, leads Alliance A062101 – a phase I/II trial to test t

• Read more

Alliance Presents Results From AMBASSADOR Trial for Patients with High-Risk Muscle -Invasive Bladder Cancer at ESMO 2024 and Published in New England Journal of Medicine

September 17, 2024

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder. Researchers found that postsurgical treatment with pembrolizumab (K

• Read more